Baxter, bioMerieux announce AKI biomarker collaboration | Q BioMed signs research deal to develop biomarker test for glaucoma | Oxford BioDynamics' biomarker assay to be used in prostate cancer trial
March 20, 2019
AACC SmartBrief
Business Perspective
Baxter, bioMerieux announce AKI biomarker collaboration
Baxter and bioMerieux are partnering on the development of biomarkers for acute kidney injury. The team at Astute Medical, which was recently acquired by bioMerieux, will develop the biomarkers in hopes of improving patient care and quickly identifying AKI.
MassDevice (Boston) (3/19) 
LinkedIn Twitter Facebook Email
Q BioMed signs research deal to develop biomarker test for glaucoma
McMaster University's Biointerfaces Institute, based in Ontario, signed a research collaboration with Q BioMed and its technology partner Mannin Research to develop a GDF15 biomarker diagnostic kit that can be used to monitor glaucoma severity and progression. The goal is to develop prototype assays ideal for point-of-care testing.
Seeking Alpha (3/19) 
LinkedIn Twitter Facebook Email
Oxford BioDynamics' biomarker assay to be used in prostate cancer trial
Oxford BioDynamics agreed to join a clinical trial conducted by Imperial College London that aims to evaluate different methods of prostate cancer screening. As part of the deal, Oxford will use its EpiSwitch diagnostic biomarker assay to assess trial participants for prostate cancer.
Compelo/Medical Devices (3/20) 
LinkedIn Twitter Facebook Email
Elevate the standard of care for women
With the BD MAX Vaginal Panel one clinician- or patient-collected vaginal swab provides results for the three most common causes of vaginitis - Bacterial Vaginosis (BV), Vulvovaginal Candidiasis (VVC), and Trichomonas vaginalis (TV). Click here to learn more.
Science Briefs
Study finds lipid testing underutilized during pregnancy
Data on 5,101 women who attended a postpartum visit within 180 days of giving birth showed 78% had not had a lipid screening before the postpartum date, researchers reported at the American College of Cardiology's annual meeting. Researcher Dipika Gopal said the study should be a call to action to encourage lipid screening in pregnant women.
Healio (free registration)/Cardiology Today (3/17) 
LinkedIn Twitter Facebook Email
Hormonal birth control failure might be due to genetic mutation
The reason hormonal birth control methods aren't 100% effective, even in compliant patients, may be due to a genetic mutation in some women, according to a study published in Obstetrics & Gynecology. Researchers say about 5% of women are genetically predisposed to produce an enzyme that lessens the effectiveness of hormonal birth control.
Wired (tiered subscription model) (3/12) 
LinkedIn Twitter Facebook Email
Epigenetic protein may become therapeutic target for AML
British researchers discovered that the epigenetic protein EZH2 could become a novel therapeutic target in patients with acute myeloid leukemia. EZH2 delays disease development until the disease is established, but after that point it promotes tumor growth.
Genetic Engineering & Biotechnology News (3/19) 
LinkedIn Twitter Facebook Email
Tech Briefs
Walgreens agrees to sell Concepta's fertility monitoring system in UK
Walgreens Boots Alliance signed a deal to sell in the UK Concepta Diagnostics' CE-marked myLotus at-home fertility monitoring system, which consists of an app and fertility monitor designed to help women measure their luteinizing hormone levels at home, calculate their most fertile days and determine whether they are pregnant. Concepta Chair Matthew Walls said the company, in partnership with Walgreens, expects to launch myLotus in other EU markets in the coming months.
MobiHealthNews (3/13) 
LinkedIn Twitter Facebook Email
Business/Corporate Briefs
Protagen purchased by Oncimmune for over $4.6M in all-share deal
Oncimmune Holdings entered into an all-share deal to acquire German firm Protagen for over $4.6 million. Oncimmune CEO Adam Hill said the deal "will accelerate Oncimmune's product discovery process, will grow our library of known and novel immunogenic proteins, and will underpin the group's ability to deliver value through the development of complementary diagnostics, a key component of our three-year forward strategy."
Morningstar/Alliance News (3/19) 
LinkedIn Twitter Facebook Email
Everstone acquires stake in CPC Diagnostics
Everstone Group, through its health care platform Everlife, acquired an undisclosed stake in CPC Diagnostics, an India-based medical device company that exports products to Middle East and European countries.
The Times of India/Times News Network (3/14) 
LinkedIn Twitter Facebook Email
Webinar: Monitoring Pregnancy with Clinical Laboratory Tests
Dr. Alison Woodworth will describe a variety of clinical laboratory tests that are available to determine the well-being of the mother as well as the fetus and to assess the risk of complications. March 27, 2019.
LinkedIn Twitter Facebook Email
Professional Practice in Clinical Chemistry Conference
The Professional Practice in Clinical Chemistry conference is designed to expand your knowledge and confidence when advising and engaging with the healthcare team. April 25-27, 2019
LinkedIn Twitter Facebook Email
Learn more about AACC:
AACC Homepage | AACC Membership | Annual Meeting
Clinical Laboratory News | Clinical Chemistry | JALM
Sign Up
SmartBrief offers 200+ newsletters
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Contributing Editor  -  Genna Rollins
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  April Hollis
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2019 SmartBrief, Inc.®
Privacy Policy (updated May 25, 2018) |  Legal Information